Global Health and WASH Funding Surges in May 2026 With 14 New Opportunities

May 4, 2026 - 14:08

The May update for global health and water, sanitation, and hygiene funding brings 14 new calls that cluster around three major shifts reshaping the landscape. Funders are moving from encouraging LMIC participation to requiring it as a hard eligibility rule. Pharmaceutical and corporate-linked funders are running independent education and research portfolios at substantial scale. And artificial intelligence adoption has shifted from speculative tool to operational requirement across health and WASH systems.

LMIC Research Leadership Becomes a Requirement, Not Just Encouragement

Wellcome anchors this shift with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility structure. The ESIC Hubs program, offering 1.5 to 1.9 million pounds per hub over three to five years, explicitly requires an LMIC-based lead applicant. This treats Global South leadership as a design constraint rather than a participation goal.

Wellcome's Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. The larger Infectious Disease Clinical Trial Award, offering 1 million to 8 million pounds for optimizing licensed interventions, requires the administering organization to be in eligible LMIC regions with at least 50 percent of applicants based there.

The same pattern appears at smaller scale across other funders. CHINNOVA channels 1 million dollars into West and Central African research institutions for climate-health work. IBRO's Neuroscience Training Grants explicitly tier ceilings by region of residence, with Africa receiving the highest amount at 5,000 dollars. IHME's GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher. Sidaction's HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement.

These calls signal a meaningful shift in how research equity is being operationalized. It is no longer encouragement language at the bottom of a call. It is now a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted.

Pharma-Funded Independent Education and Use-Inspired Research

The lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks. These include a Migraine and Women's Health RFP with 200,000 dollars over two years from a 500,000 dollar pool, Migraine IME with 200,000 dollars from a 1 million dollar pool, JAK Inhibitor evidence-based education at 100,000 dollars, and Maternal Vaccination HCP Education in Saudi Arabia at 75,000 dollars. Pfizer also runs a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia at 400,000 dollars per project.

Novo Nordisk Foundation runs four parallel calls of its own at substantial scale. Infectious Diseases Catalyst Grants have a 60 million Danish kroner pool with up to 7 million kroner for collaborative projects. Non-Diabetic Endocrinology Collaborative Grants have a 53 million kroner pool with 5 to 10 million kroner per project. Pioneer Innovator Grant Health offers 1.1 million kroner, and Distinguished Innovator Grant Health offers 6.8 million kroner. LEO Foundation deploys 2 to 4 million kroner per project for dermatology research excellence.

Pfizer's framing across calls deliberately separates the funding from product promotion. The emphasis is on measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk's use-inspired hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern is clear: industry-aligned funders are running structurally independent portfolios at meaningful dollar amounts that fund implementation evidence, not promotion.

AI as Operational Capability, Not Speculation

Several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements. Wellcome's ESIC Hubs frames AI as the accelerator for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines.

UNICEF Venture Fund's new Climate Tech for Children's Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments. The strict requirement is that solutions must already have a working prototype with promising pilot results.

The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints. One focuses on GenAI and Agentic AI in water utilities at 200,000 dollars. The other focuses on alternatives to water shutoffs and explicitly screens for implementation economics evidence.

Nordic Innovation's quantum technology call at 4.5 million Norwegian kroner extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers 300,000 euros in subsidized testing infrastructure for European healthcare AI and robotics SMEs.

The pattern is clear: